Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/15/26
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook TranscriptSeeking Alpha • 03/27/26
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/13/26
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/10/26
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational UpdatePRNewsWire • 03/10/26
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026PRNewsWire • 03/03/26
Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 01/30/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTGlobeNewsWire • 01/20/26
ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate UpdatesPRNewsWire • 01/08/26
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/08/26
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/15/25
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL TranscriptSeeking Alpha • 12/03/25
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaPRNewsWire • 12/03/25
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/18/25
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/25
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational UpdatePRNewsWire • 11/10/25
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025PRNewsWire • 11/03/25